[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100651443":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":12,"locations":7,"responsibleParty":18,"collaborators":7,"id":20,"slug":21,"hasResults":22,"nctId":23,"briefTitle":24,"officialTitle":25,"acronym":7,"eligibilityCriteria":26,"healthyVolunteers":22,"sex":27,"minAge":28,"maxAge":7,"enrollmentInfo":29,"targetDuration":7,"studyType":32,"phases":7,"briefSummary":33,"conditions":34,"keywords":36,"overallStatus":43,"whyStopped":7,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":7},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",null,[9],{"type":10,"name":11,"description":11,"armGroupLabels":7,"otherNames":7},"OTHER","IMFINZI",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",{"type":19,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100651443","a-multicenter-observational-pms-study-assessing-durvalumab-safety-in-indian-adults-with-resectable-nsclc-100651443",false,"NCT07760519","A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLC","A Prospective, Observational, Multicenter, Post Marketing Surveillance Study to Assess Safety of Durvalumab in Indian Adult Patients With Resectable Non-Small Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\n1. Patients with newly diagnosed previously untreated resectable NSCLC (tumors ≥ 4 cm and\u002For node positive) and no known EGFR mutations or ALK rearrangements prescribed with durvalumab as per local prescriber information.\n2. Provision of signed, written and dated informed consent\n\nExclusion Criteria:\n\n1. Presence of unresectable or metastatic disease.\n2. Prior treatment with durvalumab for any other indications\n3. Requires concurrent treatment for cancers other than resectable NSCLC\n4. Concurrently participating in any other clinical trial\n5. Patients with active or prior autoimmune disease or with medical conditions that required systemic corticosteroids or immunosuppressants\n6. Any condition that, in the opinion of the investigator, would interfere with the patient's participation in the study.","ALL","18 Years",{"count":30,"type":31},78,"ESTIMATED","OBSERVATIONAL","This will be a single-arm, multicenter, prospective, observational, real-world study and the data source is the patients' medical record at each site. A total of 78 patients will be enrolled in the study.",[35],"Carcinoma, Non-Small-Cell Lung",[37,38,39,40,41,42],"Durvalumab","NSCLC","post marketing surveillance","Real-world","Observational","Indian","NOT_YET_RECRUITING","2026-08-10",{"date":46,"type":47},"2026-08-12","ACTUAL",{"date":49,"type":31},"2026-09-30",{"date":51,"type":31},"2030-04-30",{"name":5,"class":6}]